Intercept Pharmaceuticals | Frais De Vente Et D'Administration



Selling And Administration Expenses Changement Date
Acadia Pharmaceuticals USD 126.37M 3.71M 2025-03
Alnylam Pharmaceuticals USD 239.95M 55.39M 2025-03
Amarin USD 36.57M 397K 2025-03
Amgen USD 1.69B 191M 2025-03
Arrowhead Research USD 27.89M 2.3M 2025-03
AstraZeneca USD 3.59B 1.96B 2025-03
Biogen USD 572.5M 104.8M 2025-03
Bristol-Myers Squibb USD 1.58B 521M 2025-03
Eli Lilly USD 2.36B 62.3M 2025-03
Gilead Sciences USD 1.26B 603M 2025-03
GlaxoSmithKline GBP 2.06B 603M 2025-03
Incyte USD 325.69M 1.02M 2025-03
Ionis Pharmaceuticals USD 76M 12.08M 2025-03
Moderna USD 212M 139M 2025-03
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Novartis USD 3.5B 368M 2024-12
PTC Therapeutics USD 161.92M 77.24M 2025-03
Regeneron Pharmaceuticals USD 633M 159.2M 2025-03
Sarepta Therapeutics USD 133.63M 30.24M 2025-03
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12



Intercept Pharmaceuticals Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Jul 2025.